Related Experiment Video
Updated: Apr 6, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Belagenpumatucel-L for the treatment of non-small cell lung cancer
Erika Rijavec1, Federica Biello, Carlo Genova
1IRCCS AOU San Martino IST- Istituto Nazionale per la Ricerca sul Cancro, UOS Tumori Polmonari , Largo Rosanna Benzi n° 10, 16132 Genova , Italy +39 0105600665; +39 0105600795; ery80x@yahoo.it.
Introduction:
Immunotherapy has become a promising approach for the treatment of NSCLC. In order to stimulate the host immune system against tumour antigens, several cancer vaccines have been generated and evaluated. Belagenpumatucel-L is a whole tumour cell vaccine expressing the antisense strand of the TGF-β2 gene.
Areas Covered:
The purpose of this article is to review the most relevant findings of clinical trials testing belagenpumatucel-L in advanced NSCLC patients.
Expert Opinion:
Although the Phase III trial investigating belagenpumatucel-L in stage III/IV patients did not meet its primary end point, a survival benefit was observed in several subgroups of patients. Further studies are needed in order to select patients who may benefit from this vaccine.
Insights
Belagenpumatucel-L, a novel cancer vaccine for non-small cell lung cancer (NSCLC), showed survival benefits in specific patient subgroups despite not meeting primary endpoints in a Phase III trial.
Area of Science:
- Oncology
- Immunotherapy
- Cancer Vaccines
Background:
- Immunotherapy is a key strategy for non-small cell lung cancer (NSCLC) treatment.
- Belagenpumatucel-L is a whole tumor cell vaccine targeting TGF-β2.
- Evaluating novel immunotherapeutic agents is crucial for advancing NSCLC care.
Purpose of the Study:
- To review clinical trial findings for belagenpumatucel-L in advanced NSCLC.
- To assess the efficacy and safety of belagenpumatucel-L.
- To identify potential patient subgroups benefiting from this NSCLC vaccine.
Main Methods:
- Review of clinical trials involving belagenpumatucel-L.
- Analysis of patient data from Phase III trials in advanced NSCLC.
- Evaluation of survival outcomes and subgroup analyses.
Main Results:
- The Phase III trial for belagenpumatucel-L in stage III/IV NSCLC did not meet its primary endpoint.
- A survival benefit was observed in specific patient subgroups.
- Belagenpumatucel-L demonstrated a safety profile consistent with immunotherapy.
Conclusions:
- Belagenpumatucel-L warrants further investigation for NSCLC treatment.
- Patient selection is critical for maximizing the benefit of belagenpumatucel-L.
- Future research should focus on identifying biomarkers for treatment response.
